Intranasal administration of glial-derived neurotrophic factor (GDNF) rapidly and significantly increases whole-brain GDNF level in rats

Neuroscience

Volumn 303, Issue , 2015, Pages 569-576

  Bender, T S ^a   Migliore, M M ^b   Campbell, R B ^b   John Gatley, S ^a   Waszczak, B L ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Autoradiography; Glial cell line derived neurotrophic factor (GDNF); Intranasal, liposomes; Neuroprotection; Parkinson's disease

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LIPOSOME; PHOSPHATE BUFFERED SALINE; IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFICACY; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; SPRAGUE DAWLEY RAT; TIME FACTOR;

ADMINISTRATION, INTRANASAL; ANALYSIS OF VARIANCE; ANIMALS; AUTORADIOGRAPHY; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IODINE ISOTOPES; MALE; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 84938099480     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.07.016     Document Type: Article

References (37)

1. Alexi T., Borlongan C.V., Faull R.L., Williams C.E., Clark R.G., Gluckman P.D., Hughes P.E. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog Neurobiol 2000, 60:409-470.
2. Aoi M., Date I., Tomita S., Ohmoto T. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci Res 2000, 36:319-325.
3. Boger H.A., Middaugh L.D., Huang P., Zaman V., Smith A.C., Hoffer B.J., Tomac A.C., Granholm A.C. A partial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp Neurol 2006, 202:336-347.
4. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002, 5:514-516.
5. Bowenkamp K.E., Hoffman A.F., Gerhardt G.A., Henry M.A., Biddle P.T., Hoffer B.J., Granholm A.C. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol 1995, 355:479-489.
6. Cohen A.D., Zigmond M.J., Smith A.D. Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: time course of protection and neurorestoration. Brain Res 2011, 1370:80-88.
7. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010, 99:1654-1673.
8. Ding Y.M., Jaumotte J.D., Signore A.P., Zigmond M.J. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J Neurochem 2004, 89:776-787.
9. Fernandez-Espejo E. Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. Mol Neurobiol 2004, 29:15-30.
10. Gash D.M., Zhang Z., Gerhardt G. Neuroprotective and neurorestorative properties of GDNF. Ann Neurol 1998, 44:S121-S125.
11. Graff C.L., Pollack G.M. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 2005, 94:1187-1195.
12. Granholm A.C., Reyland M., Albeck D., Sanders L., Gerhardt G., Hoernig G., Shen L., Westphal H., Hoffer B. Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J Neurosci 2000, 20:3182-3190.
13. Grondin R., Gash D.M. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. J Neurol 1998, 245:P35-P42.
14. Hanson L.R., Fine J.M., Hoekman J.D., Nguyen T.M., Burns R.B., Martinez P.M., Pohl J., Frey W.H. Intranasal delivery of growth differentiation factor 5 to the central nervous system. Drug Deliv 2012, 19:149-154.
15. Hawkes C.H., Shephard B.C., Daniel S.E. Is Parkinson's disease a primary olfactory disorder?. QJM 1999, 92:473-480.
16. Hovland D.N., Boyd R.B., Butt M.T., Engelhardt J.A., Moxness M.S., Ma M.H., Emery M.G., Ernst N.B., Reed R.P., Zeller J.R., Gash D.M., Masterman D.M., Potter B.M., Cosenza M.E., Lightfoot R.M. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol 2007, 35:676-692.
17. Hurelbrink C.B., Barker R.A. The potential of GDNF as a treatment for Parkinson's disease. Exp Neurol 2004, 185:1-6.
18. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today 2002, 7:1184-1189.
19. Kearns C.M., Cass W.A., Smoot K., Kryscio R., Gash D.M. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J Neurosci 1997, 17:7111-7118.
20. Kirik D., Georgievska B., Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 2004, 7:105-110.
21. Krieglstein K., Suter-Crazzolara C., Unsicker K. Development of mesencephalic dopaminergic neurons and the transforming growth factor-beta superfamily. J Neural Transm Suppl 1995, 46:209-216.
22. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
23. Lochhead J.J., Thorne R.G. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012, 64:614-628.
24. Lochhead J.J., Wolak D.J., Pizzo M.E., Thorne R.G. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J Cereb Blood Flow Metab 2015, 35:371-381.
25. Malerba F., Paoletti F., Capsoni S., Cattaneo A. Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin Drug Deliv 2011, 8:1277-1296.
26. McNamara M.C., Miller A.T., Davis J.N. Influence of freezing and storage methods on concentrations of brain DOPA and 5 HTP after pretreatment with a decarboxylase inhibitor. Res Commun Chem Pathol Pharmacol 1977, 16:569-572.
27. Migliore M.M., Vyas T.K., Campbell R.B., Amiji M.M., Waszczak B.L. Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci 2010, 99:1745-1761.
28. Migliore M.M., Ortiz R., Dye S., Campbell R.B., Amiji M.M., Waszczak B.L. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease. Neuroscience 2014, 274:11-23.
29. Misra A., Ganesh S., Shahiwala A., Shah S.P. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003, 6:252-273.
30. Renner D.B., Svitak A.L., Gallus N.J., Ericson M.E., Frey W.H., Hanson L.R. Intranasal delivery of insulin via the olfactory nerve pathway. J Pharm Pharmacol 2012, 64:1709-1714.
31. Ross T.M., Zuckermann R.N., Reinhard C., Frey W.H. Intranasal administration delivers peptoids to the rat central nervous system. Neurosci Lett 2008, 439:30-33.
32. Scranton R.A., Fletcher L., Sprague S., Jimenez D.F., Digicaylioglu M. The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS. PLoS ONE 2011, 6:e18711.
33. Sullivan A.M., Opacka-Juffry J., Blunt S.B. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur J Neurosci 1998, 10:57-63.
34. Thorne R.G., Frey W.H. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001, 40:907-946.
35. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127:481-496.
36. Thorne R.G., Hanson L.R., Ross T.M., Tung D., Frey W.H. Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 2008, 152:785-797.
37. Yang J.P., Liu H.J., Cheng S.M., Wang Z.L., Cheng X., Yu H.X., Liu X.F. Direct transport of VEGF from the nasal cavity to brain. Neurosci Lett 2009, 449:108-111.